TRANSLATIONAL ONCOLOGY PROGRAM

翻译肿瘤学(TO)计划的使命是开发促进互动的临床试验 基础科学家、转化型科学家和临床医生之间的合作，以促进改善临床结果。 在上一次审查期间，该方案分为以下三个主题领域，即 在针对疾病的工作组中强调：(1)开发和开展早期临床试验， 目标是将调查结果转化为合作小组或第三阶段背景；(2)促进纳入预测性 和临床试验中的预后生物标志物；(3)开发与以下相关的新的治疗方法 抗血管生成药物、信号通路和活性氧(ROS)。为了促进跨计划的 以及方案内互动和翻译活动、疾病特定的翻译 最近成立了黑色素瘤、乳腺癌、Gl、前列腺和宫颈/妇科工作小组(TWGs 癌症。与翻译终点相结合的临床试验已经通过方案间开发 与其他项目的合作，包括肿瘤成像(新辅助乳房)和癌的发生和 信号(慢性粒细胞白血病、前列腺)。在过去的五年里，我们的计划专注于临床研究的收益 试验，包括假设驱动试验、研究人员发起试验(HDII)、合作小组试验和制药试验 赞助的审判。重点放在HDII试验上，以开发UCI丰富的综合癌症 集中资源开发癌症护理的新方法。HDII在过去六年中的应计利润 从2002-2004年的60个急剧增长到2005-2007年的175个。总体介入临床试验应计， 不包括化学预防试验，2002-2003年为142项，2004-2005年增至218项，2005年迄今为387项 2005-2007年，特别重要的是，应计项目的这种增长与导致 经同行审查的资金和在影响较大的期刊上发表的出版物数量增加。 TO计划有25名成员，代表8个部门和1所学校，在 与癌症相关的直接同行审查资助，其中10个项目由NCI资助，直接总数为 1187,498美元。2007年，会员共出版了71本刊物，其中62本与癌症有关。 其中44%是内部关系，16%是内部关系。

The Translational Oncology (TO) Program's mission is to develop clinical trials that promote interaction between basic scientists, translational scientists, and clinicians to facilitate improved clinical outcomes. During the last review period the Program was organized into the following three thematic areas that are emphasized in disease-specific working groups: (1) Develop and carry out early phase clinical trials with a goal to translate findings into the cooperative group or phase III setting; (2) Facilitate inclusion of predictive and prognostic biomarker profiles in clinical trials; (3) Develop novel therapeutic approaches related to antiangiogenesis agents, signaling pathways and reactive oxygen species (ROS). In order to promote interprogrammatic and intra-programmatic interactions and translational activities, disease specific translational working groups (TWGs) were recently established for melanoma, breast, Gl, prostate and cervical/GYN cancers. Clinical trials coupled to translational endpoints have been developed through inter-programatic collaborations with other Programs, including Oncoimaging (Neoadjuvant breast), and Cacinogenesis and Signaling (CML, prostate). Over the past five years, our Program has focused on accrual to clinical research trials, including Hypothesis-driven, investigator-initiated trials (HDII), cooperative group, and pharmaceutical sponsored trials. Emphasis has been placed on HDII trials to exploit UCI's rich Comprehensive Cancer Center resources to develop novel approaches to cancer care. HDII accrual over the past six years has grown dramatically from 60 in 2002-2004 to 175 in 2005-2007. Overall interventional clinical trials accrual, excluding chemoprevention trials, was 142 in 2002-2003, increasing to 218 in 2004-2005, and 387 to date in 2005-2007, Of particular significance, this growth in accrual was linked to translational endpoints that led to peer reviewed funding and increased numbers of publications in high impact journals. The TO Program has 25 Members, representing eight Departments and one School, and has $2,024,203 in direct cancer-related peer-reviewed funding, 10 projects of which are funded by NCI for a direct total of $1,187,498. In 2007, Members published a total of 71 publications with 62 of those being cancer-related of which 44% were inter- and 16% were intra-related.